{
    "clinical_study": {
        "@rank": "110854", 
        "arm_group": [
            {
                "arm_group_label": "PHGG", 
                "arm_group_type": "Experimental", 
                "description": "2.5gr per day for the first week and then 5gr per day for 11 weeks."
            }, 
            {
                "arm_group_label": "Maltodextrin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2.5gr per day for the first week and then 5gr per day for 11 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study objective is to assess the short and long term effects of partially hydrolyzed\n      guar gum (PHGG) administration on clinical symptoms of IBS and quality of life of these\n      patients."
        }, 
        "brief_title": "The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "IBS", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fulfillment of the Rome III criteria for IBS.\n\n          -  Aged 20-68 years at the time of screening.\n\n          -  Provision of written informed consent.\n\n          -  Commitment of availability throughout the 6 months study period.\n\n        Exclusion Criteria:\n\n          -  Major abdominal surgery in the past.\n\n          -  The presence of any active (organic)GI disease.\n\n          -  Past or present major medical or psychiatric illness.\n\n          -  Any concomitant disease.\n\n          -  Alarming symptoms (rectal bleeding, weight loss, etc.)\n\n          -  Pregnancy.\n\n          -  Family history of colorectal carcinoma or inflammatory bowel disease (IBD).\n\n          -  Abnormal laboratory studies (blood biochemistry , liver enzymes,complete blood\n             count), abnormal thyroid function.\n\n          -  Non-adjusted diet in the case of lactose or gluten intolerance.\n\n          -  Recent travel to regions with endemic parasitic diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779765", 
            "org_study_id": "TASMC-12-NV-242-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "PHGG", 
                "intervention_name": "PHGG", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Maltodextrin", 
                "intervention_name": "Maltodextrin", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "IBS", 
            "Diarrhea", 
            "Constipation", 
            "Fibers"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "email": "vaisman@tasmc.health.gov.il", 
                "last_name": "Nachum Vaisman, MD", 
                "phone": "972-3-6974807"
            }, 
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "64239"
                }, 
                "name": "Tel Aviv Sourasky Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study", 
        "overall_contact": {
            "email": "vaisman@tasmc.health.gov.il", 
            "last_name": "Nachum Vaisman, MD", 
            "phone": "972-3-6974807"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IBS scoring - Francis severity IBS score.", 
            "measure": "Improvement in IBS score.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "reference": [
            {
                "PMID": "11053260", 
                "citation": "Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, Read N, Silk D, Whorwell P. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000 Nov;47 Suppl 2:ii1-19."
            }, 
            {
                "PMID": "14645642", 
                "citation": "Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003 Nov 27;349(22):2136-46. Review."
            }, 
            {
                "PMID": "12184518", 
                "citation": "Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, Battaglia G, Desideri S, Faedo A, Marzolino C, Tonon A, Ermani M, Leandro G. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci. 2002 Aug;47(8):1697-704."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779765"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Quality of life - by the IBS - quality of life questionnaire - Drossman Patrick.", 
            "measure": "Quality questionnaire", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Tel-Aviv Sourasky Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tel-Aviv Sourasky Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}